Skip to content
Open access

BAG3+ CAF-T cell neighborhood predicts resistance to neoadjuvant chemoimmunotherapy in NSCLC

Jul 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 40 references
Medicine

TL;DR

The BAG3+ CAF-T Cell Neighborhood may serve as a biomarker for predicting non-response to NCIT in NSCLC, with significant potential to inform clinical decision-making.

Abstract

Background Despite significantly improving outcomes in non-small cell lung cancer (NSCLC), neoadjuvant chemoimmunotherapy (NCIT) fails to achieve a major pathological response (MPR) in over 40% of patients. Consequently, the early identification of non-responders prior to treatment initiation remains a critical unmet clinical need. Methods In this study, we performed single-cell RNA sequencing (scRNA-seq) on pre-treatment NSCLC tissue samples and integrated data from two public databases to identify signaling pathways associated with poor treatment response. Key findings were subsequently validated using multiplex immunofluorescence (mIF), and the predictive value of identified molecules was finally assessed in our cohort and GEO datasets. Results Among the 83 patients, 23/57 (40.35%) of these radiological responders failed to achieve MPR. Data analysis revealed activation of stress-related signaling pathways in cancer-associated fibroblasts (CAFs) and T cells from nMPR patients, with elevated expression of stress-related markers, including BAG3 and IFITM2. MIF confirmed that BAG3+IFITM2+ CAFs and BAG3+CD8+ T cells were spatially adjacent and significantly more abundant in nMPR patients. In our cohort and the two public databases, the BAG3+ CAF-T Cell Neighborhood was significantly more abundant in the nMPR group compared to the MPR group (p<0.05). In the MPR group, there was no significant difference in BAG3+ CAF-T Cell Neighborhood between the radiological PR and non-PR subgroups. The AUC values of BAG3+IFITM2+ CAFs, BAG3+CD8+ T cells, and the BAG3+ CAF-T Cell Neighborhood were 0.84 [95%CI: 0.746-0.931], 0.72 [95%CI: 0.603-0.835], and 0.87 [95%CI: 0.787-0.948], respectively. The OS and DFS of the BAG3+ CAF-T Cell Neighborhood high group are significantly decreased than that of the low group (p<0.05). The level of BAG3+ CAF-T Cell Neighborhood outperformed other two indicators in predicting non-response to NCIT. Consistent results were observed in GSE126044 and GSE135222. Conclusion The BAG3+ CAF-T Cell Neighborhood may serve as a biomarker for predicting non-response to NCIT in NSCLC, with significant potential to inform clinical decision-making.

Read PDF

Similar papers

Open access Sep 2026

OLR1 as a Key Inflammatory Regulator Associated with Poor Response to Neoadjuvant Immunochemotherapy in Resectable Lung Cancer

Targeting OLR1 may represent a promising strategy to enhance immunotherapy efficacy and improve clinical outcomes in patients with resectable lung cancer, but the study is limited by a relatively small validation cohort and a strong reliance on bioinformatics analyses.

Xin-Xian Chen, Siang Zhang, Xue-Feng Ai et al. · 0 citations
Open access Aug 2026

Multi-omics identification of MBNL2 associated with poor pathological response to neoadjuvant chemoimmunotherapy in lung squamous cell carcinoma

A 25-gene prognostic model for LUSC is established and MBNL2 is identified as a novel correlate of poor pathological response to NACI, laying a foundation for future mechanistic investigation.

Hao Wu, Yang Cheng, Hong-Lin Yan et al. · 0 citations
Open access Jul 2026

DUSP5 contributes to platinum resistance in ovarian cancer: single-cell discovery and functional validation

Findings support DUSP5 as a candidate biomarker and therapeutic target that warrants further mechanistic and clinical validation and contribute to platinum response and resistance by linking tumor-intrinsic adaptive programs with TME-associated features in ovarian cancer.

Cheng-Feng Liu, Wehua Li, Tingjun Liao et al. · 0 citations
Aug 2026

OA06-LBA01.4. A Multimodal Classifier to Stratify Response to Neoadjuvant Chemoimmunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma Based on RCT-HCHTOG1909

The esophageal cancer multimodal immuno-chemotherapy classifier (EMIC), which effectively stratifies patients into two groups with distinct therapeutic responses: EMIC1 (predicted to benefit from combined immuno-chemotherapy) and EMIC2 (predicted to have equivalent outcomes with chemotherapy alone), providing a rationa...

Yan Zheng, Wen-Qun Xing, Ji Wang et al. · 0 citations
Open access Sep 2026

51 Discovery of Exhausted CD8+ T-cell States Associated with Clinical Outcomes in Renal Cell Carcinoma

It is found that baseline tumor infiltration by exhausted T cells with a resident memory phenotype (Tex-rm) is significantly associated with worse PFS in advanced RCC patients receiving ICI monotherapy or ICI+TKI combination therapy.

Zhao-Chen Ye, S. Kashima, Rishabh Rout et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.